To include your compound in the COVID-19 Resource Center, submit it here.

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors continue to have an appetite for new listings.

Late Thursday, ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) priced 7.5 million shares at $16, raising $120

Read the full 561 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers